RheaVita has joined forces with IMA Life to develop and commercialise RheaVita's continuous biopharmaceutical freeze drying technology.
Through the partnership, RheaVita will receieve funding from IMA Life — as well as ongoing support — to get its tech to the market.
According to the Ghent University spinoff, its freeze-drying technology integrates all the steps generally associated with pharmaceutical freeze-drying into a single continuous and controlled production line.
This initiative aims to allow biopharmaceutical companies to accelerate process development, while also boosting flexibility and ensuring consistent product quality.
It's been specifically designed for the single vial level — specifically for high-value, low-volume products such as cell and gene therapies, monoclonal antibodies, RNA therapies, ADCs, vaccines and other precision medicines.
Biopharmaceutical companies can accelerate process development, while also boosting flexibility and ensuring consistent product quality
By optimising the freeze-drying process of advanced therapeutics, IMA Life and RheaVita hope to benefit the pharmaceutical industry, while also catering to the growing needs of patients worldwide.
CEO and co-founder of RheaVita, Prof. Dr Thomas De Beer, commented: “Our partnership with IMA Life represents a major opportunity to accelerate our technology and expand its market reach,”
“Collaborating with an industry leader like IMA Life in aseptic pharmaceutical production technology not only strengthens our development and equipment manufacturing capabilities but also provides confidence to our end-users with respect to the robustness and reliability of our solutions. With IMA Life’s extensive expertise and global footprint, we’re well-positioned to bring our continuous freeze-drying solution to biopharmaceutical manufacturers worldwide, providing a fast, flexible and reliable alternative to conventional batch freeze-drying.”
Michele Arduini, Managing Director at IMA Life, said: “RheaVita’s continuous freeze-drying technology is a future-proof solution for the flexible and extremely well-controlled production of increasingly complex biopharmaceutical drugs."
"We anticipate a growing need for low-volume, high-value production, and RheaVita’s technology is ideally suited for this demand. Each unit produced with RheaVita’s system is subject to rigorous, individual product quality control, ensuring that every single dose meets the highest standards."
"This level of control makes the RheaVita solution an invaluable asset for biopharmaceutical companies looking to guarantee consistent product quality in the most efficient way possible.”